It was shown that a single intravenous dose of H-IPSE (H-IPSEH06) given to mice was more effective than 2-mercaptoethane sulfonate sodium (MESNA), the current drug of choice for mitigating CHC, in an IL-4-dependent manner (120). The gene discussed is IL4; the disease is cryohydrocytosis.